MX9709094A - Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina. - Google Patents
Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina.Info
- Publication number
- MX9709094A MX9709094A MX9709094A MX9709094A MX9709094A MX 9709094 A MX9709094 A MX 9709094A MX 9709094 A MX9709094 A MX 9709094A MX 9709094 A MX9709094 A MX 9709094A MX 9709094 A MX9709094 A MX 9709094A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulations
- camptothecin derivatives
- highly lipophilic
- lipophilic camptothecin
- highly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Abstract
Una formulacion farmacéutica en forma de una solucion o suspension de pH de 2 a 6, de camptotecina o de un derivado lipofilo de la camptotecina, que tiene una solubilidad en agua inferior a 5 æg/ml, en N-metilpirrolidin-2-ona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/461,385 US5726181A (en) | 1995-06-05 | 1995-06-05 | Formulations and compositions of poorly water soluble camptothecin derivatives |
PCT/EP1996/002438 WO1996039143A1 (en) | 1995-06-05 | 1996-06-04 | Pharmaceutical formulations of highly lipophilic camptothecin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9709094A true MX9709094A (es) | 1998-03-31 |
Family
ID=23832347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9709094A MX9709094A (es) | 1995-06-05 | 1996-06-04 | Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina. |
Country Status (12)
Country | Link |
---|---|
US (7) | US5726181A (es) |
EP (1) | EP0831825B1 (es) |
JP (1) | JP4009877B2 (es) |
CN (1) | CN1101679C (es) |
AT (1) | ATE238053T1 (es) |
AU (1) | AU694677B2 (es) |
DE (1) | DE69627651T2 (es) |
DK (1) | DK0831825T3 (es) |
ES (1) | ES2191760T3 (es) |
MX (1) | MX9709094A (es) |
PT (1) | PT831825E (es) |
WO (1) | WO1996039143A1 (es) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
IT1282673B1 (it) * | 1996-02-23 | 1998-03-31 | Ist Naz Stud Cura Dei Tumori | Derivati della camptotecina e loro uso come agenti antitumorali |
WO1998007727A1 (en) * | 1996-08-19 | 1998-02-26 | Bionumerik Pharmaceuticals, Inc. | Highly lipophilic camptothecin derivatives |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
CO4940469A1 (es) | 1997-03-05 | 2000-07-24 | Sugen Inc | Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
US20030059465A1 (en) * | 1998-05-11 | 2003-03-27 | Unger Evan C. | Stabilized nanoparticle formulations of camptotheca derivatives |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
IL134592A0 (en) * | 1998-06-18 | 2001-04-30 | Univ George Washington | Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects |
US6043367A (en) * | 1998-09-30 | 2000-03-28 | Roffler; Steve | Proactive antitumor compounds |
WO2000021370A1 (en) | 1998-10-14 | 2000-04-20 | University Of Kentucky Research Foundation | Oligonucleotide delivery systems for camptothecins |
US6057303A (en) * | 1998-10-20 | 2000-05-02 | Bionumerik Pharmaceuticals, Inc. | Highly lipophilic Camptothecin derivatives |
US6017948A (en) * | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
US6040330A (en) * | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US7064114B2 (en) | 1999-03-19 | 2006-06-20 | Parker Hughes Institute | Gel-microemulsion formulations |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
PT1178952E (pt) | 1999-05-14 | 2007-12-04 | Univ California | Novos moduladores da interleucina-1 e do factor alfa de necrose tumoral, síntese dos referidos moduladores e métodos de utilização dos referidos moduladores |
IL146480A0 (en) | 1999-05-14 | 2002-07-25 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
DK1189637T3 (da) * | 1999-05-17 | 2006-12-11 | Cancer Res Ventures Ltd | Produkter til forbedring af biotilgængeligheden for oralt indgivne medikamenter |
US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US6228855B1 (en) | 1999-08-03 | 2001-05-08 | The Stehlin Foundation For Cancer Research | Aromatic esters of camptothecins and methods to treat cancers |
GB9918885D0 (en) | 1999-08-10 | 1999-10-13 | Pharmacia & Upjohn Spa | Pharmaceutical formulations in hydroxypropymethycellulose capsules |
EP2266607A3 (en) | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US6420378B1 (en) * | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
WO2001028517A1 (fr) * | 1999-10-20 | 2001-04-26 | Teijin Limited | Compositions therapeutiques aqueuses |
SE9903831D0 (sv) | 1999-10-22 | 1999-10-22 | Astra Ab | Formulation of substituted benzimidazoles |
US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
EP1259608B1 (en) | 2000-02-23 | 2009-08-12 | Life Technologies Corporation | Modified fluorescent proteins |
US20030148996A1 (en) * | 2000-03-31 | 2003-08-07 | Joseph Rubinfeld | Camptothecin complexes |
JP2004527456A (ja) * | 2000-08-09 | 2004-09-09 | イムクローン システムズ インコーポレイティド | Egf受容体拮抗剤による過増殖性の疾患の治療 |
PL363618A1 (en) | 2000-11-09 | 2004-11-29 | Neopharm, Inc. | Sn-38 lipid complexes and methods of use |
JP4395549B2 (ja) * | 2000-11-16 | 2010-01-13 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | 薬物及び発酵生成物の発見のための海洋放線菌分類群 |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
US6653319B1 (en) | 2001-08-10 | 2003-11-25 | University Of Kentucky Research Foundation | Pharmaceutical formulation for poorly water soluble camptothecin analogues |
US20030134003A1 (en) * | 2001-10-09 | 2003-07-17 | Medigreen Biotechnology Inc. | Method of using geranium oil and sophora root extracts as a supporting composition in cancer treatments |
US6960346B2 (en) * | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
AU2003296897A1 (en) * | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
US7112581B2 (en) * | 2002-09-27 | 2006-09-26 | Nereus Pharmaceuticals, Inc. | Macrocyclic lactams |
WO2004103344A1 (en) * | 2003-05-20 | 2004-12-02 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
US20040258754A1 (en) * | 2003-06-18 | 2004-12-23 | Valery Alakhov | Compositions for oral administration of camptothecin and its analogs |
US8217072B2 (en) * | 2003-06-20 | 2012-07-10 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US20050049294A1 (en) * | 2003-06-20 | 2005-03-03 | Michael Palladino | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
US7067666B2 (en) * | 2003-06-27 | 2006-06-27 | Research Triangle Institute | 7-substituted camptothecin and camptothecin analogs and methods for producing the same |
US7619059B2 (en) * | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
CA2445420A1 (en) * | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
CN1852740B (zh) * | 2003-09-17 | 2011-05-11 | 耐科塔医药公司 | 多支链聚合物的药物前体 |
CA2541265A1 (en) * | 2003-10-08 | 2005-04-28 | Novartis Ag | Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
US20050208146A1 (en) * | 2003-10-30 | 2005-09-22 | Pfizer Inc | Novel dosage and administration method for oral camptosar |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
WO2005060871A1 (en) * | 2003-12-17 | 2005-07-07 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of camptothecins and process for making same |
KR20060132698A (ko) * | 2004-01-23 | 2006-12-21 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 항균제로 유용한 비스-인돌 피롤 |
JP4734319B2 (ja) * | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
US7276530B2 (en) | 2004-04-30 | 2007-10-02 | Nereus Pharmaceuticals, Inc. | [3.2.0] Heterocyclic compounds and methods of using the same |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
US20060003976A1 (en) * | 2004-06-04 | 2006-01-05 | Yuehua Zhang | Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds |
JP4433918B2 (ja) * | 2004-07-15 | 2010-03-17 | コニカミノルタエムジー株式会社 | 画像形成方法 |
US20060094692A1 (en) * | 2004-10-28 | 2006-05-04 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of camptothecins and process for making same |
NZ554677A (en) * | 2004-11-05 | 2010-08-27 | Samyang Corp | Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents |
KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
GT200500310A (es) * | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
CN103230394B (zh) * | 2004-12-03 | 2016-04-20 | 达纳-法伯癌症研究公司 | 治疗肿瘤性疾病的化合物及其用途 |
US8196848B2 (en) * | 2005-04-29 | 2012-06-12 | Pratt & Whitney Rocketdyne, Inc. | Gasifier injector |
SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
WO2007015757A2 (en) | 2005-07-21 | 2007-02-08 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
ITRM20050418A1 (it) * | 2005-08-04 | 2007-02-05 | Sigma Tau Ind Farmaceuti | Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina. |
CN101232872A (zh) * | 2005-08-10 | 2008-07-30 | 诺瓦提斯公司 | 7-(叔丁氧基)亚氨基甲基喜树碱的制剂 |
AU2006277879A1 (en) * | 2005-08-10 | 2007-02-15 | Novartis Ag | Microparticle compositions of the topoisomerase I inhibitor 7-tert-butoxyiminomethylcamptothecin |
TW200731990A (en) | 2005-12-16 | 2007-09-01 | Sonus Pharma Inc | Lipophilic anticancer drug compounds, compositions, and related methods |
WO2007075825A2 (en) * | 2005-12-20 | 2007-07-05 | Sonus Pharmaceuticals, Inc. | Lipophilic anticancer drug compounds |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
US20080039485A1 (en) * | 2006-08-08 | 2008-02-14 | Targetgen Biotechnology Co., Ltd. | Low-dose-long-term pharmaceutical composition comprising camptothecin derivatives for the treatment of cancers |
WO2008021549A2 (en) * | 2006-08-18 | 2008-02-21 | Sidney Kimmel Cancer Center | Methods and compositions for topoisomerase i modulated tumor suppression |
KR100946275B1 (ko) * | 2006-09-26 | 2010-03-08 | 주식회사 삼양사 | 수 난용성 캄토테신 유도체의 미세 나노입자 및 그의제조방법 |
KR101441709B1 (ko) | 2006-11-30 | 2014-09-18 | 넥타르 테라퓨틱스 | 중합체 컨쥬게이트의 제조 방법 |
PE20081482A1 (es) * | 2006-12-20 | 2008-12-23 | Novartis Ag | Capsulas de gelatina que contienen un acido |
WO2008095195A2 (en) * | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
KR20090108082A (ko) * | 2007-02-09 | 2009-10-14 | 엔존 파마슈티컬즈, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법 |
US20090017167A1 (en) * | 2007-07-11 | 2009-01-15 | Herbalife International Inc. | Mixture and beverage made therefrom for protecting cellular hydration |
US7687497B2 (en) | 2007-10-16 | 2010-03-30 | Bionumerik Pharmaceuticals, Inc. | C10-substituted camptothecin analogs |
WO2009051580A1 (en) | 2007-10-16 | 2009-04-23 | Bionumerik Pharmaceuticals, Inc. | C7-substituted camptothecin analogs |
US7687496B2 (en) | 2007-10-16 | 2010-03-30 | Bionumerik Pharmaceuticals, Inc. | C7-substituted camptothecin analogs |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
EP2257220B1 (en) * | 2008-03-13 | 2017-06-14 | Liebel-Flarsheim Company LLC | Multi-function, foot-activated controller for imaging system |
WO2009140287A1 (en) * | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Salinosporamide derivatives as proteasome inhibitors |
CA2732508C (en) | 2008-08-11 | 2016-03-15 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
WO2010025337A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
PT2349346T (pt) | 2008-09-23 | 2019-10-24 | Nektar Therapeutics | Método de dosagem metronómica com profármacos de camptotecina (e.g. peg-irinotecano). |
WO2010048018A1 (en) * | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US20110207760A1 (en) * | 2010-02-23 | 2011-08-25 | Valery Alakhov | Sn-38 compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
CA2959965A1 (en) | 2014-09-02 | 2016-03-10 | Bhupinder Singh | Pharmaceutical formulations comprising tetrahydrocurcumin and lipids |
CA2963923A1 (en) | 2014-10-08 | 2016-04-14 | Pacific Northwest Research Institute | Methods and compounds for increasing the potency of antifungal agents |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
US10610591B2 (en) | 2017-03-15 | 2020-04-07 | Nanoco Technologies Ltd. | Light responsive quantum dot drug delivery system |
EP3773612A4 (en) | 2018-03-28 | 2022-01-12 | Herbalife International of America, Inc. | ACETYLATION OF POLYSACCHARIDS |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4473692A (en) * | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
DE3682874D1 (de) * | 1985-10-21 | 1992-01-23 | Daiichi Seiyaku Co | Pyranoindolizinderivate und verfahren zu ihrer herstellung. |
US5034397A (en) * | 1985-12-12 | 1991-07-23 | Bristol-Myers Squibb Co. | Stable, water soluble salt compositions of M-AMSA in 1-methyl-2-pyrrolidinone |
US4772589A (en) * | 1986-10-29 | 1988-09-20 | Bristol-Myers | Etoposide solution in NMP |
JPH0615547B2 (ja) * | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
CA2056445A1 (en) * | 1989-05-26 | 1990-11-27 | Ho-Wah Hui | Injectable clarithromycin composition |
AU6974191A (en) * | 1989-12-20 | 1991-07-18 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
SK283693B6 (sk) * | 1990-09-28 | 2003-12-02 | Smithkline Beecham Corporation | Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli |
TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
US5447936A (en) * | 1993-12-22 | 1995-09-05 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof |
ATE220894T1 (de) * | 1993-12-29 | 2002-08-15 | Matrix Pharma | Zusammensetzung für lokale freigabe von zytostatika |
US5468754A (en) * | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
-
1995
- 1995-06-05 US US08/461,385 patent/US5726181A/en not_active Expired - Lifetime
-
1996
- 1996-06-04 WO PCT/EP1996/002438 patent/WO1996039143A1/en active IP Right Grant
- 1996-06-04 EP EP96920792A patent/EP0831825B1/en not_active Expired - Lifetime
- 1996-06-04 DK DK96920792T patent/DK0831825T3/da active
- 1996-06-04 PT PT96920792T patent/PT831825E/pt unknown
- 1996-06-04 MX MX9709094A patent/MX9709094A/es active IP Right Grant
- 1996-06-04 AU AU62223/96A patent/AU694677B2/en not_active Ceased
- 1996-06-04 ES ES96920792T patent/ES2191760T3/es not_active Expired - Lifetime
- 1996-06-04 AT AT96920792T patent/ATE238053T1/de active
- 1996-06-04 CN CN96194482A patent/CN1101679C/zh not_active Expired - Lifetime
- 1996-06-04 DE DE69627651T patent/DE69627651T2/de not_active Expired - Lifetime
- 1996-06-04 JP JP50014797A patent/JP4009877B2/ja not_active Expired - Fee Related
- 1996-06-21 US US08/667,424 patent/US5880133A/en not_active Expired - Lifetime
-
1997
- 1997-10-22 US US08/955,947 patent/US5958937A/en not_active Expired - Lifetime
- 1997-10-22 US US08/956,084 patent/US5859022A/en not_active Expired - Lifetime
- 1997-10-22 US US08/955,955 patent/US5900419A/en not_active Expired - Lifetime
- 1997-10-22 US US08/955,956 patent/US5955467A/en not_active Expired - Lifetime
- 1997-10-22 US US08/958,210 patent/US5859023A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69627651D1 (de) | 2003-05-28 |
DE69627651T2 (de) | 2003-10-16 |
US5955467A (en) | 1999-09-21 |
US5859023A (en) | 1999-01-12 |
US5900419A (en) | 1999-05-04 |
US5880133A (en) | 1999-03-09 |
US5859022A (en) | 1999-01-12 |
EP0831825B1 (en) | 2003-04-23 |
CN1187126A (zh) | 1998-07-08 |
PT831825E (pt) | 2003-09-30 |
CN1101679C (zh) | 2003-02-19 |
JP4009877B2 (ja) | 2007-11-21 |
JPH11506463A (ja) | 1999-06-08 |
AU6222396A (en) | 1996-12-24 |
ATE238053T1 (de) | 2003-05-15 |
US5726181A (en) | 1998-03-10 |
EP0831825A1 (en) | 1998-04-01 |
DK0831825T3 (da) | 2003-08-04 |
AU694677B2 (en) | 1998-07-23 |
US5958937A (en) | 1999-09-28 |
WO1996039143A1 (en) | 1996-12-12 |
ES2191760T3 (es) | 2003-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9709094A (es) | Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina. | |
NZ287857A (en) | Delivery of water insoluble active agents using tocopherol as emulsifier or solvent | |
UA40663C2 (uk) | Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання | |
CA2289202A1 (en) | Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent | |
MY116665A (en) | Camptothecin derivatives | |
MX9707428A (es) | Formulaciones de analogos de insulina monomericos. | |
NZ501066A (en) | Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin | |
IL103571A0 (en) | Water soluble camptothecin derivatives,their preparation and pharmaceutical compositions containing them | |
AP9801378A0 (en) | 9-amino-3- keto erythromycin derivatives. | |
BG103750A (en) | Salt of a derivative of naphthyridinecarbonic acid | |
IL117889A0 (en) | Pharmaceutical compositions containing lipophilic compounds | |
IL102814A0 (en) | Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them | |
BR9611571B1 (pt) | composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal. | |
MX9706605A (es) | Derivados de indol como antagonistas de los aminoacidos exitadores. | |
BG104436A (en) | The administration of macrolides for the treatment of cancer and macular degeneration | |
IL118162A0 (en) | Nanoparticles for oral administration of pharmaceutical agents of low solubility | |
MXPA03005221A (es) | Composicion farmaceutica de dronedarona para administracion parenteral. | |
HUP9900987A3 (en) | Camptothecin derivatives process for their preparation, use thereof as antitumor agents and pharmaceutical compositions containing them | |
AU5691796A (en) | Terpenoidic derivatives useful as antitumor agents | |
WO2001030391A3 (en) | Pharmaceutical composition containing midazolam | |
WO1999005103A3 (en) | 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent | |
CA2223259A1 (en) | Pharmaceutical formulations of highly lipophilic camptothecin derivatives | |
IL109470A0 (en) | Water soluble camptothecin derivatives, their preparation and pharmaceutical compositions containing them | |
EP0737476A3 (en) | A pharmaceutical preparation containing a 3-(2H)-furanone derivative for prevention and/or treatment of cataracts | |
WO1996041646A3 (en) | Pharmaceutical compositions containing lornoxicam and cyclodextrin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |